Abstract
B-lymphoblastic leukemia/lymphoma (B-ALL) BCR-ABL1-like (Ph-like) is a provisional entity in the 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The incidence of Ph-like ALL is 15-30% in children and young adults with B-ALL. Genetic abnormalities associated with Ph-like ALL are heterogenous. Approximately 50% of Ph-like ALL patients may have cytokine receptor like factor 2 (CRLF2) gene overexpression, JAK2 mutations with activation of JAK-STAT pathway and a poor clinical outcome. Due to recent advances in the genomic testing of B-ALL, patients can be stratified into different risk groups based on early treatment response to drugs and minimal residual disease (MRD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
